Search

Search results

Ascenion’s portfolio company OMEICOS extends Series B financing to address new indications

OMEICOS Therapeutics, a spin-off from the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), announced the second closing of its Series B financing round with US-based REMIGES Ventures. The financing enables OMEICOS to establish a US-based subsidiary in Cambridge Massachusetts and to expand its technology into the field of eye diseases. The company plans to evaluate a range of compounds and different routes of administration for different types of eye diseases.

In the first quarter of 2017, OMEICOS reported the first closing of a Series B financing and initiated a Phase I trial with its lead compound OMT-28. So far, clinical development has focused on cardiovascular diseases, namely atrial fibrillation, the most common cardiac arrhythmia in humans.

For further information see:

OMEICOS press release